Harmony Biosciences Holdings, Inc. (HRMY) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 13 analysts15.7% Below Target
HRMY trades 15.7% below Wall Street's consensus target of $44.25.
Current Price$38.26
Average Target$44.25
Target
Current
Low$36.00
Median$45.50
High$50.00
Analyst Target Range
Forward P/E11.2x
(Value)
PEG Ratio—
Implied Growth+38.4%
(High Growth)
Analyst Spread31.6%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes HRMY achieves its forward estimates and maintains a stable P/E multiple of 11.2x. This scenario reflects the blended consensus of 13 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
HRMY Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Harmony Biosciences Holdings, Inc. (HRMY) has a Wall Street consensus price target of $44.25, based on estimates from 13 covering analysts. With the stock currently trading at $38.26, this represents a potential upside of +15.7%. The company has a market capitalization of $2.21B.
Analyst price targets range from a low of $36.00 to a high of $50.00, representing a 32% spread in expectations. The median target of $45.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, HRMY trades at a trailing P/E of 14.1x and forward P/E of 11.2x. Analysts expect EPS to grow +38.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $47.17, with bear and bull scenarios of $29.71 and $62.15 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+29.9%
Industry Consensus
Avg Forward P/E
36.6x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 JAZZJazz Pharmaceuticals plc | $15.5B | $247.72 | $257.44 | +3.9% | Buy | 9.8x | 48 |
 AVPTAvePoint, Inc. | $2.7B | $12.51 | $15.00 | +19.9% | Buy | 31.0x | 12 |
 AXSMAxsome Therapeutics, Inc. | $12.9B | $249.76 | $262.38 | +5.1% | Buy | — | 26 |
 INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.7B | $47.41 | $65.00 | +37.1% | Buy | 19.1x | 14 |
 NKTRNektar Therapeutics | $1.5B | $74.90 | $149.60 | +99.7% | Buy | — | 33 |
 PTCTPTC Therapeutics, Inc. | $7.4B | $89.20 | $95.83 | +7.4% | Buy | 100.7x | 26 |
 RAREUltragenyx Pharmaceutical Inc. | $3.5B | $35.87 | $47.11 | +31.3% | Buy | — | 33 |
 ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
 CRLCharles River Laboratories International, Inc. | $11.0B | $228.68 | $222.11 | -2.9% | Buy | 20.6x | 37 |
HRMY — Frequently Asked Questions
Quick answers to the most common questions about buying HRMY stock.
What is the HRMY stock price target for 2026?
Harmony Biosciences Holdings, Inc. (HRMY) has a consensus 12-month price target of $44.25, implying 15.7% upside from $38.26. The 13 analysts covering HRMY see moderate appreciation potential.
Is HRMY a buy, sell, or hold?
HRMY has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $44.25 implies 15.7% upside from current levels.
Is HRMY stock overvalued or undervalued?
With a forward P/E of 11.1584x, HRMY trades at a relatively low valuation. The consensus target of $44.25 implies 15.7% appreciation, suggesting meaningful undervaluation.
How high can HRMY stock go?
The most bullish Wall Street analyst has a price target of $50 for HRMY, while the most conservative target is $36. The consensus of $44.25 represents the median expectation. Our quantitative valuation model projects a bull case target of $62 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover HRMY stock?
HRMY is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 2 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the HRMY stock forecast?
The 12-month HRMY stock forecast based on 13 Wall Street analysts shows a consensus price target of $44.25, with estimates ranging from $36 (bear case) to $50 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $47, with bear/bull scenarios of $30/$62.
What is HRMY's fair value based on fundamentals?
Our quantitative valuation model calculates HRMY's fair value at $47 (base case), with a bear case of $30 and bull case of $62. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
What is HRMY's forward P/E ratio?
HRMY trades at a forward P/E ratio of 11.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy HRMY stock?
Wall Street analysts are optimistic on HRMY, with a "Buy" consensus rating and $44.25 price target (15.7% upside). 9 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do HRMY price targets vary so much?
HRMY analyst price targets range from $36 to $50, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.25 consensus represents the middle ground. Our model's $30-$62 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare